O	O	O	0	10	Activation	Activation	B-NP	NN	O	0	ROOT	O
O	O	O	11	13	of	of	B-PP	IN	O	1	NMOD	O
O	O	O	14	19	human	human	B-NP	JJ	O	8	NMOD	O
O	O	O	20	36	immunodeficiency	immunodeficiency	I-NP	NN	O	8	NMOD	O
O	O	O	37	42	virus	virus	I-NP	NN	O	8	NMOD	O
O	O	O	43	47	type	type	I-NP	NN	O	8	NMOD	O
O	O	O	48	49	1	1	I-NP	CD	O	8	NMOD	O
O	O	O	50	60	expression	expression	I-NP	NN	O	2	PMOD	O
O	O	O	61	63	by	by	B-PP	IN	O	1	NMOD	O
O	O	O	64	75	Gardnerella	Gardnerella	B-NP	FW	O	11	NMOD	O
O	O	O	76	85	vaginalis	vaginalis	I-NP	FW	O	9	PMOD	O
O	O	O	85	86	.	.	O	.	O	1	P	O

O	O	O	88	97	Bacterial	Bacterial	B-NP	JJ	O	2	NMOD	O
O	O	O	98	107	vaginosis	vaginosis	I-NP	NN	O	6	SUB	O
O	O	O	108	109	(	(	O	(	O	5	DEP	O
O	O	O	109	111	BV	BV	B-NP	NN	O	5	DEP	O
O	O	O	111	112	)	)	O	)	O	2	NMOD	O
O	O	O	113	115	is	be	B-VP	VBZ	O	28	VMOD	O
O	O	O	116	126	associated	associate	I-VP	VBN	O	6	VC	O
O	O	O	127	131	with	with	B-PP	IN	O	7	VMOD	O
O	O	O	132	134	an	an	B-NP	DT	O	11	NMOD	O
O	O	O	135	144	increased	increase	I-NP	VBN	O	11	NMOD	O
O	O	O	145	149	rate	rate	I-NP	NN	O	8	PMOD	O
O	O	O	150	152	of	of	B-PP	IN	O	11	NMOD	O
O	O	O	153	159	sexual	sexual	B-NP	JJ	O	14	NMOD	O
O	O	O	160	172	transmission	transmission	I-NP	NN	O	12	PMOD	O
O	O	O	173	175	of	of	B-PP	IN	O	14	NMOD	O
O	O	O	176	181	human	human	B-NP	JJ	O	18	NMOD	O
O	O	O	182	198	immunodeficiency	immunodeficiency	I-NP	NN	O	18	NMOD	O
O	O	O	199	204	virus	virus	I-NP	NN	O	22	NMOD	O
O	O	O	205	206	(	(	O	(	O	21	DEP	O
O	O	O	206	209	HIV	HIV	B-NP	NN	O	21	DEP	O
O	O	O	209	210	)	)	O	)	O	18	NMOD	O
O	O	O	211	215	type	type	B-NP	NN	O	15	PMOD	O
O	O	O	216	217	1	1	I-NP	CD	O	22	NMOD	O
O	O	O	217	218	,	,	O	,	O	28	P	O
O	O	O	219	222	and	and	O	CC	O	28	VMOD	O
O	O	O	223	234	Gardnerella	Gardnerella	B-NP	FW	O	27	NMOD	O
O	O	O	235	244	vaginalis	vaginalis	I-NP	FW	O	28	SUB	O
O	O	O	245	247	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	O	248	258	frequently	frequently	I-VP	RB	O	28	VMOD	O
O	O	O	259	267	isolated	isolate	I-VP	VBN	O	28	VC	O
O	O	O	268	272	from	from	B-PP	IN	O	30	VMOD	O
O	O	O	273	276	the	the	B-NP	DT	O	34	NMOD	O
O	O	O	277	284	genital	genital	I-NP	JJ	O	34	NMOD	O
O	O	O	285	291	tracts	tract	I-NP	NNS	O	31	PMOD	O
O	O	O	292	294	of	of	B-PP	IN	O	34	NMOD	O
O	O	O	295	300	women	woman	B-NP	NNS	O	35	PMOD	O
O	O	O	301	305	with	with	B-PP	IN	O	36	NMOD	O
O	O	O	306	308	BV	BV	B-NP	NN	O	37	PMOD	O
O	O	O	308	309	.	.	O	.	O	28	P	O

O	O	O	310	311	G	G	B-NP	NN	O	4	NMOD	O
O	O	O	311	312	.	.	I-NP	FW	O	4	NMOD	O
O	O	O	313	322	vaginalis	vaginalis	I-NP	FW	O	4	NMOD	O
O	O	O	323	330	lysates	lysate	I-NP	NNS	O	5	SUB	O
O	O	O	331	335	were	be	B-VP	VBD	O	0	ROOT	O
O	O	O	336	341	found	find	I-VP	VBN	O	5	VC	O
O	O	O	342	344	to	to	I-VP	TO	O	9	VMOD	O
O	O	O	345	358	significantly	significantly	I-VP	RB	O	9	VMOD	O
O	O	O	359	368	stimulate	stimulate	I-VP	VB	O	6	VMOD	O
O	O	O	369	372	HIV	HIV	B-NP	NN	O	11	NMOD	O
O	O	O	373	383	expression	expression	I-NP	NN	O	9	OBJ	O
O	O	O	384	386	in	in	B-PP	IN	O	11	NMOD	O
O	O	O	387	397	monocytoid	monocytoid	B-NP	JJ	B-cell_type	14	NMOD	B-cell_type
O	O	O	398	403	cells	cell	I-NP	NNS	I-cell_type	12	PMOD	I-cell_type
O	O	O	403	404	.	.	O	.	O	5	P	O

O	O	O	405	416	Stimulation	Stimulation	B-NP	NN	O	2	SUB	O
O	O	O	417	420	was	be	B-VP	VBD	O	0	ROOT	O
O	O	O	421	434	significantly	significantly	B-ADJP	RB	O	4	AMOD	O
O	O	O	435	441	higher	high	I-ADJP	JJR	O	2	PRD	O
O	O	O	442	446	when	when	B-ADVP	WRB	O	2	VMOD	O
O	O	O	447	454	lysates	lysate	B-NP	NNS	O	7	SUB	O
O	O	O	455	459	were	be	B-VP	VBD	O	5	SBAR	O
O	O	O	460	466	heated	heat	I-VP	VBN	O	7	VC	O
O	O	O	467	469	at	at	B-PP	IN	O	8	VMOD	O
O	O	O	470	473	100	100	B-NP	CD	O	11	NMOD	O
O	O	O	474	481	degrees	degree	I-NP	NNS	O	9	PMOD	O
O	O	O	482	483	C	C	B-ADJP	JJ	O	11	NMOD	O
O	O	O	484	487	for	for	B-PP	IN	O	8	VMOD	O
O	O	O	488	489	5	5	B-NP	CD	O	15	NMOD	O
O	O	O	490	493	min	min	I-NP	NN	O	13	PMOD	O
O	O	O	494	497	but	but	O	CC	O	2	VMOD	O
O	O	O	498	501	was	be	B-VP	VBD	O	2	VMOD	O
O	O	O	502	509	reduced	reduce	I-VP	VBN	O	17	VC	O
O	O	O	510	512	by	by	B-PP	IN	O	18	VMOD	O
O	O	O	513	522	treatment	treatment	B-NP	NN	O	19	PMOD	O
O	O	O	523	527	with	with	B-PP	IN	O	20	NMOD	O
O	O	O	528	536	lysozyme	lysozyme	B-NP	NN	B-protein	24	NMOD	B-protein
O	O	O	537	539	or	or	I-NP	CC	O	24	NMOD	O
O	O	O	540	548	protease	protease	I-NP	NN	B-protein	21	PMOD	B-protein
O	O	O	548	549	.	.	O	.	O	2	P	O

O	O	O	550	551	G	G	B-NP	NN	O	4	NMOD	O
O	O	O	551	552	.	.	I-NP	SYM	O	4	NMOD	O
O	O	O	553	562	vaginalis	vaginalis	I-NP	NN	O	4	NMOD	O
O	O	O	563	570	lysates	lysate	I-NP	NNS	O	6	SUB	O
O	O	O	571	575	also	also	B-ADVP	RB	O	6	VMOD	O
O	O	O	576	585	activated	activate	B-VP	VBD	O	0	ROOT	O
O	O	O	586	589	HIV	HIV	B-NP	NN	O	8	NMOD	O
O	O	O	590	600	expression	expression	I-NP	NN	O	6	OBJ	O
O	O	O	601	603	in	in	B-PP	IN	O	8	NMOD	O
O	O	O	604	611	certain	certain	B-NP	JJ	O	9	PMOD	O
O	O	O	612	613	T	T	I-NP	NN	B-cell_line	13	NMOD	B-cell_line
O	O	O	614	618	cell	cell	I-NP	NN	I-cell_line	13	NMOD	I-cell_line
O	O	O	619	624	lines	line	I-NP	NNS	I-cell_line	10	NMOD	I-cell_line
O	O	O	624	625	.	.	O	.	O	6	P	O

O	O	O	626	627	G	G	B-NP	NN	O	4	NMOD	O
O	O	O	627	628	.	.	I-NP	FW	O	4	NMOD	O
O	O	O	629	638	vaginalis	vaginalis	I-NP	FW	O	4	NMOD	O
O	O	O	639	646	lysates	lysate	I-NP	NNS	O	5	SUB	O
O	O	O	647	656	activated	activate	B-VP	VBD	O	0	ROOT	O
T1	B-Entity	B-Entity	657	660	HIV	HIV	B-NP	NN	B-DNA	11	NMOD	B-DNA
T1	I-Entity	I-Entity	661	665	long	long	I-NP	JJ	I-DNA	11	NMOD	I-DNA
T1	I-Entity	I-Entity	665	666	-	-	I-NP	HYPH	I-DNA	11	NMOD	I-DNA
T1	I-Entity	I-Entity	666	674	terminal	terminal	I-NP	JJ	I-DNA	11	NMOD	I-DNA
T1	I-Entity	I-Entity	675	681	repeat	repeat	I-NP	NN	I-DNA	11	NMOD	I-DNA
O	O	O	682	695	transcription	transcription	I-NP	NN	O	5	OBJ	O
O	O	O	696	698	in	in	B-PP	IN	O	11	NMOD	O
O	O	O	699	702	HIV	HIV	B-NP	NN	B-cell_type	16	NMOD	B-cell_type
O	O	O	702	703	-	-	B-NP	HYPH	I-cell_type	16	NMOD	I-cell_type
O	O	O	703	711	infected	infect	I-NP	VBN	I-cell_type	16	NMOD	I-cell_type
O	O	O	712	717	cells	cell	I-NP	NNS	I-cell_type	12	PMOD	I-cell_type
O	O	O	718	721	and	and	O	CC	O	5	VMOD	O
O	O	O	722	731	increased	increase	B-NP	VBN	O	23	NMOD	O
T2	B-Entity	B-Entity	732	734	NF	NF	I-NP	NN	B-protein	21	NMOD	B-protein
T2	I-Entity	I-Entity	734	735	-	-	B-NP	HYPH	I-protein	21	NMOD	I-protein
T2	I-Entity	I-Entity	735	741	kappaB	kappaB	I-NP	NN	I-protein	23	NMOD	I-protein
O	O	O	742	749	binding	binding	I-NP	NN	O	23	NMOD	O
O	O	O	750	758	activity	activity	I-NP	NN	O	5	OBJ	O
O	O	O	758	759	,	,	O	,	O	5	P	O
O	O	O	760	770	indicating	indicate	B-VP	VBG	O	5	VMOD	O
O	O	O	771	773	an	an	B-NP	DT	O	27	NMOD	O
O	O	O	774	780	effect	effect	I-NP	NN	O	25	OBJ	O
O	O	O	781	783	by	by	B-PP	IN	O	27	NMOD	O
O	O	O	784	785	G	G	B-NP	NN	O	31	NMOD	O
O	O	O	785	786	.	.	I-NP	FW	O	31	NMOD	O
O	O	O	787	796	vaginalis	vaginalis	I-NP	FW	O	28	PMOD	O
O	O	O	797	799	on	on	B-PP	IN	O	27	NMOD	O
O	O	O	800	803	HIV	HIV	B-NP	NN	O	34	NMOD	O
O	O	O	804	817	transcription	transcription	I-NP	NN	O	32	PMOD	O
O	O	O	817	818	.	.	O	.	O	5	P	O

O	O	O	819	822	The	The	B-NP	DT	O	2	NMOD	O
O	O	O	823	833	activation	activation	I-NP	NN	O	10	SUB	O
O	O	O	834	836	of	of	B-PP	IN	O	2	NMOD	O
O	O	O	837	840	HIV	HIV	B-NP	NN	O	5	NMOD	O
O	O	O	841	851	production	production	I-NP	NN	O	3	PMOD	O
O	O	O	852	854	by	by	B-PP	IN	O	2	NMOD	O
O	O	O	855	856	G	G	B-NP	NN	O	6	PMOD	O
O	O	O	856	857	.	.	I-NP	FW	O	9	NMOD	O
O	O	O	858	867	vaginalis	vaginalis	I-NP	FW	O	7	NMOD	O
O	O	O	868	876	suggests	suggest	B-VP	VBZ	O	0	ROOT	O
O	O	O	877	881	that	that	B-SBAR	IN	O	10	VMOD	O
O	O	O	882	889	genital	genital	B-NP	JJ	O	14	NMOD	O
O	O	O	890	895	tract	tract	I-NP	NN	O	14	NMOD	O
O	O	O	896	905	infection	infection	I-NP	NN	O	19	SUB	O
O	O	O	906	910	with	with	B-PP	IN	O	14	NMOD	O
O	O	O	911	912	G	G	B-NP	NN	O	18	NMOD	O
O	O	O	912	913	.	.	I-NP	FW	O	18	NMOD	O
O	O	O	914	923	vaginalis	vaginalis	I-NP	FW	O	15	PMOD	O
O	O	O	924	933	increases	increase	B-VP	VBZ	O	11	SBAR	O
O	O	O	934	937	the	the	B-NP	DT	O	21	NMOD	O
O	O	O	938	942	risk	risk	I-NP	NN	O	19	OBJ	O
O	O	O	943	945	of	of	B-PP	IN	O	21	NMOD	O
O	O	O	946	949	HIV	HIV	B-NP	NN	O	24	NMOD	O
O	O	O	950	962	transmission	transmission	I-NP	NN	O	22	PMOD	O
O	O	O	963	965	by	by	B-PP	IN	O	19	VMOD	O
O	O	O	966	976	increasing	increase	B-VP	VBG	O	25	PMOD	O
O	O	O	977	980	HIV	HIV	B-NP	NN	O	28	NMOD	O
O	O	O	981	991	expression	expression	I-NP	NN	O	26	OBJ	O
O	O	O	992	994	in	in	B-PP	IN	O	28	NMOD	O
O	O	O	995	998	the	the	B-NP	DT	O	32	NMOD	O
O	O	O	999	1006	genital	genital	I-NP	JJ	O	32	NMOD	O
O	O	O	1007	1012	tract	tract	I-NP	NN	O	29	PMOD	O
O	O	O	1012	1013	.	.	O	.	O	10	P	O

O	O	O	1014	1018	This	This	B-NP	DT	O	2	SUB	O
O	O	O	1019	1022	may	may	B-VP	MD	O	0	ROOT	O
O	O	O	1023	1030	explain	explain	I-VP	VB	O	2	VC	O
O	O	O	1030	1031	,	,	O	,	O	3	P	O
O	O	O	1032	1034	at	at	B-ADVP	IN	O	7	PMOD	O
O	O	O	1035	1040	least	least	I-ADVP	JJS	O	5	AMOD	O
O	O	O	1041	1043	in	in	B-PP	IN	O	3	VMOD	O
O	O	O	1044	1048	part	part	B-NP	NN	O	7	PMOD	O
O	O	O	1048	1049	,	,	O	,	O	3	P	O
O	O	O	1050	1053	the	the	B-NP	DT	O	12	NMOD	O
O	O	O	1054	1063	increased	increase	I-NP	VBN	O	12	NMOD	O
O	O	O	1064	1068	rate	rate	I-NP	NN	O	3	OBJ	O
O	O	O	1069	1071	of	of	B-PP	IN	O	12	NMOD	O
O	O	O	1072	1075	HIV	HIV	B-NP	NN	O	15	NMOD	O
O	O	O	1076	1088	transmission	transmission	I-NP	NN	O	13	PMOD	O
O	O	O	1089	1091	in	in	B-PP	IN	O	12	NMOD	O
O	O	O	1092	1097	women	woman	B-NP	NNS	O	16	PMOD	O
O	O	O	1098	1102	with	with	B-PP	IN	O	17	NMOD	O
O	O	O	1103	1105	BV	BV	B-NP	NN	O	18	PMOD	O
O	O	O	1105	1106	.	.	O	.	O	2	P	O
